AdcetrisTM (brentuximab vedotin) is a drug used to help reduce tumor size in people with Hodgkin's lymphoma or a type of non-Hodgkin's lymphoma known as systemic anaplastic large cell lymphoma (ALCL). This chemotherapy medicine is approved for use in adults only and should only be given when other forms of treatment have been unsuccessful.
Adcetris is administered into a vein (as an intravenous, or IV, infusion) by a healthcare provider every three weeks. While some people tolerate it well, most people who receive the drug will experience some type of side effect, such as nausea, diarrhea, or fatigue.
While it may be an effective medication, not everyone can use it. Information on Adcetris should be discussed with your healthcare provider before starting treatment to help avoid potential complications. For example, you may not be able to use this medicine if you have problems with your immune system, if you are taking certain medications, or if you have certain allergies.
(For more information on this medication, click Adcetris. This article offers a complete overview, including how it works, how it performed in clinical trials, and more.)
Food and Drug Administration (FDA) news release. FDA approves Adcetris to treat two types of lymphoma. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781.htm. Accessed March 16, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA approved drug products. FDA Web site. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed March 14, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click